A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/02/2004	US6811768 Use of inhaled NO as anti-inflammatory agent
11/02/2004	US6811767 Liquid droplet aerosols of nanoparticulate drugs
11/02/2004	US6810874 Two or more powder containers for different drug powders which can be inhaled as a combined medication
11/02/2004	CA2364251C Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
11/02/2004	CA2320160C Modulation of hair growth
11/02/2004	CA2317736C Bisulfate salt of hiv protease inhibitor
11/02/2004	CA2317131C Novel erythromycin derivatives
11/02/2004	CA2315614C Pyrazoles
11/02/2004	CA2301787C New derivatives of benzo[3,4]cyclobuta[1,2-c]pyrrole, the procedure for preparing them and the pharmaceutical compounds that contain them
11/02/2004	CA2296970C Neuropeptide y antagonists
11/02/2004	CA2296313C 2-aminopyridines containing fused ring substituents as nos inhibitors
11/02/2004	CA2283676C Stimulation, culture and preservation of pancreatic and other cells
11/02/2004	CA2282279C Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
11/02/2004	CA2153903C Process for the preparation of 10-desacetoxybaccatin iii
11/02/2004	CA2129040C Styryl derivatives and processes for their preparation
11/02/2004	CA2115536C Heterocyclically substituted phenyl-cyclohexane-carboxylic acid derivatives
11/02/2004	CA2112014C Antiallergic composition for ophthalmic or nasal use
11/02/2004	CA2103454C Macrocyclic immunomodulators
11/02/2004	CA2094806C Aminosulfonyl urea acat inhibitors
11/02/2004	CA2074039C Antihypertensive combination
10/2004
10/30/2004	CA2431742A1 Formulations for anaesthetic use
10/30/2004	CA2429139A1 Treatment of hormone-refractory prostate cancer
10/30/2004	CA2427258A1 Combination therapy for treatment of neoplasia
10/28/2004	WO2004092736A2 Derivatives of azithromycin
10/28/2004	WO2004092731A1 Element having bioactive substance fixed thereto
10/28/2004	WO2004092404A2 Inhibitors of acidic mammalian chitinase as asthma therapeutics
10/28/2004	WO2004092388A1 Vector
10/28/2004	WO2004092384A2 Means and methods for diagnosing and treating affective disorders
10/28/2004	WO2004092374A1 METHOD OF REGULATING ACTIVATION OF TRANSCRIPTIONAL FACTORS NF-AT, AP-1 AND NF-κB USING EFFECT OF ACTIVATING ADAPTOR PROTEIN 3BP2
10/28/2004	WO2004092352A2 Disruption of the reg pathway
10/28/2004	WO2004092346A2 Small molecule inhibition of a pdz-domain interaction
10/28/2004	WO2004092334A2 Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates
10/28/2004	WO2004092329A2 Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
10/28/2004	WO2004092223A1 Cross-linked polysaccharide composition
10/28/2004	WO2004092215A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
10/28/2004	WO2004092204A1 Identification of n-alkylglycine trimers for induction of apoptosis
10/28/2004	WO2004092196A2 Tie-2 modulators and methods of use
10/28/2004	WO2004092189A1 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
10/28/2004	WO2004092179A1 Spiro derivative, production process, and antioxidant
10/28/2004	WO2004092178A1 Benzoxepino-11-piperidylidene compounds and process for production thereof
10/28/2004	WO2004092173A2 A2a adenosine receptor antagonists
10/28/2004	WO2004092172A2 Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
10/28/2004	WO2004092171A2 Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
10/28/2004	WO2004092170A2 Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
10/28/2004	WO2004092169A1 Spiropiperidine compound and medicinal use thereof
10/28/2004	WO2004092168A1 Cgrp receptor antagonists
10/28/2004	WO2004092166A2 Cgrp receptor antagonists
10/28/2004	WO2004092165A1 3-benzhydrylidene-8-aza-bicyclo[3.2.1]octane derivatives with opioid receptor activity
10/28/2004	WO2004092164A1 Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
10/28/2004	WO2004092163A1 Phenylazole compound, production process, and antioxidant drug
10/28/2004	WO2004092162A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/28/2004	WO2004092161A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/28/2004	WO2004092153A1 Diamine derivative, production process, and antioxidizing drug
10/28/2004	WO2004092147A1 M-stage kinesin inhibitor
10/28/2004	WO2004092146A2 N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
10/28/2004	WO2004092136A1 Nitrogenous heterocyclic compound and use thereof
10/28/2004	WO2004092134A1 [c]-fused bicyclic proline derivatives and their use for treating arthritic conditions
10/28/2004	WO2004092124A2 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
10/28/2004	WO2004092123A2 Inhibitors of fungal invasion
10/28/2004	WO2004092122A2 Preparation and purification of synthetic capsaicin
10/28/2004	WO2004092121A2 Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones
10/28/2004	WO2004092120A2 Pyrimidinone compounds as calcilytics
10/28/2004	WO2004092116A1 Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
10/28/2004	WO2004092115A2 Hydroxamates as therapeutic agents
10/28/2004	WO2004091724A1 Anthranilic acid derivatives useful in treating infection with hepatitis c virus
10/28/2004	WO2004091700A1 Cartridge injection appliance, cartridge, and injection appliance set for ophthalmic use with the injection appliance
10/28/2004	WO2004091666A1 Compositions containing piperacillin and tazobactam useful for injection
10/28/2004	WO2004091665A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
10/28/2004	WO2004091664A1 Cytoplasmic malate dehydrogenase inhibitor
10/28/2004	WO2004091663A1 Drug for nerve regeneration
10/28/2004	WO2004091662A1 Agent for repairing corneal perception
10/28/2004	WO2004091660A1 Lklf/klf2 gene expression promoter
10/28/2004	WO2004091659A1 Drug for preventing or treating angiogenic eye diseases
10/28/2004	WO2004091653A1 Interferon beta in severe acute respiratory syndrome (sars)
10/28/2004	WO2004091648A1 Method for inhibiting tumor angiogenesis and tumor growth
10/28/2004	WO2004091645A2 Composition comprising rosmarinic acid, borneol and ginsenoside
10/28/2004	WO2004091642A1 Preventive or remedy for arthritis
10/28/2004	WO2004091640A1 Skin protecting compositions
10/28/2004	WO2004091636A1 Phosphate derivatives of pharmaceutical products
10/28/2004	WO2004091635A1 Remedy for endometriosis and gynecologic diseases
10/28/2004	WO2004091634A1 Composition and uses of galectin antagonists
10/28/2004	WO2004091633A1 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
10/28/2004	WO2004091632A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor
10/28/2004	WO2004091631A1 Androgen pharmaceutical composition and method for treating depression
10/28/2004	WO2004091630A1 Remedies for diseases to be applied to eye
10/28/2004	WO2004091629A1 Methods and devices for epithelial protection during photodynamic therapy
10/28/2004	WO2004091627A2 Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
10/28/2004	WO2004091626A1 Bone growth stimulation with no/statin and other no modulating combinations
10/28/2004	WO2004091624A1 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
10/28/2004	WO2004091623A1 Pharmaceutical formulations containing methylnaltrexone
10/28/2004	WO2004091622A1 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
10/28/2004	WO2004091621A1 Alternating treatment of cancer with topoisomerase i and topoisomerase ii inhibitors
10/28/2004	WO2004091620A1 Combined therapy comprising an indolopyrrolocarbazole derivative and irinotecan
10/28/2004	WO2004091619A1 A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
10/28/2004	WO2004091618A1 Polymorphic form of montelukast sodium
10/28/2004	WO2004091617A1 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)- (2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety
10/28/2004	WO2004091616A1 Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
10/28/2004	WO2004091615A1 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide for treatment of depression/anxiety
10/28/2004	WO2004091614A2 Stabilized amlodipine maleate formations
10/28/2004	WO2004091613A2 Substituted phenyl acetamides and their use as protease inhibitors

1 ... 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 4924 4925 4926 4927 4928 ... 7860